High-Dose Seasonal Flu Vaccine Ready for 2010–2011

Objective Pregnant women and unborn babies are at increased risk of complications from influenza, including pneumonia, yet in the UK, uptake of flu vaccination amongst this population remains <50%. Pregnant women hold beliefs about risks of flu and efficacy of vaccination that consistently predict them to decline vaccination. This study aimed to develop a theory and evidence-based intervention addressing these beliefs to promote flu vaccine uptake. Methods The intervention was developed by behavioural scientists, pregnant women, midwives, clinicians and Public Health professionals, informed by Intervention Mapping. Six predefined steps were performed in line with Intervention Mapping. Results The intervention is an animation addressing beliefs about risks of flu and efficacy of vaccination. Preliminary testing using qualitative methodology indicates the information within the animation is appropriate, and the animation is acceptable to pregnant women. Conclusions This is the first known intervention for pregnant women, aiming to increase flu vaccination through addressing risk and efficacy appraisals. It has been implemented within seasonal flu vaccination campaigns during 2018/19 and 2019/20 within one geographically and ethnically diverse area of the UK.

Download Full-text

A Content Analysis of Newspaper Coverage of the Seasonal Flu Vaccine in Ontario, Canada, October 2001 to March 2011

Journal of Health Communication ◽

10.1080/10810730.2016.1222038 ◽

2016 ◽

Vol 21 (10) ◽

pp. 1088-1097 ◽

Cited By ~ 17

Author(s):

Samantha B. Meyer ◽

Stephanie K. Lu ◽

Laurie Hoffman-Goetz ◽

Bryan Smale ◽

Heather MacDougall ◽

...

Keyword(s):

Content Analysis ◽

Newspaper Coverage ◽

Seasonal Flu ◽

Flu Vaccine

Download Full-text

Perspectives of Pulmonologists on the 2009-2010 H1N1 Vaccination Effort

Pulmonary Medicine ◽

10.1155/2012/306207 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6

Author(s):

Sarah J. Clark ◽

Anne E. Cowan ◽

Pascale M. Wortley

Keyword(s):

Seasonal Influenza ◽

Response Rate ◽

Influenza Pandemic ◽

National Sample ◽

H1n1 Vaccine ◽

Vaccine Recommendations ◽

Seasonal Flu ◽

Flu Vaccine ◽

Vaccination Campaigns ◽

Mailed Survey

Persons with high-risk conditions such as asthma were a target group for H1N1 vaccine recommendations. We conducted a mailed survey of a national sample of pulmonologists to understand their participation in the 2009-2010 H1N1 vaccine campaign. The response rate was 59%. The majority of pulmonologists strongly recommended H1N1 vaccine for children (73%) and adults aged 25–64 years (51%). Only 60% of respondents administered H1N1 vaccine in their practice compared to 87% who offered seasonal influenza vaccine. Other than vaccine supply, respondents who provided H1N1 vaccine reported few logistical problems. Two-thirds of respondents would be very likely to vaccinate during a future influenza pandemic; this rate was higher among those who provided H1N1 vaccine and/or seasonal flu vaccine. In total, the H1N1 vaccine-related experiences of pulmonologists seemed to be positive. However, additional efforts are needed to increase participation in future pandemic vaccination campaigns.

Download Full-text

Choice of influenza vaccine in people over 65 years old. Analysis of reports from international vaccination advisory committees

Revista Española de Quimioterapia ◽

10.37201/req/076.2021 ◽

2021 ◽

Author(s):

Alberto Pérez-Rubio ◽

◽

José Javier Castrodeza ◽

José María Eiros

Keyword(s):

Influenza Vaccine ◽

Influenza Vaccines ◽

High Dose ◽

Advisory Committees ◽

Individual Level ◽

Age Appropriate ◽

Working Groups ◽

Flu Vaccine ◽

The Individual ◽

The Uk

Introduction. Annual recommendations on influenza vaccine use in different countries are developed by influenza-specific working groups within their Immunization Advisory Committees. Adults aged 65 years and over are included in the groups for which vaccination against influenza is particularly recommended due to the morbidity associated. A variety of influenza vaccines are available, some of which boosted immunity, are licensed for use only in this specific age group, where the immune response to traditional influenza vaccines may be suboptimal. We analyze the main annual recommendations on the use of the influenza vaccine issued by advisory committees on immunization for the population over 65 years of age. Material and methods. The latest influenza vaccination guidelines have been selected and the recommendations for people over 65 years of age published by the main vaccination advisory committees have been reviewed. Results. The UK Advisory Committee (JCVI) recommends the use of Quadruvalent Inactivated Influenza Vaccine with Adjuvant (aQIV) or High Dose Quadrivalent Inactivated Influenza Vaccine (QIV-HD). The US committee (ACIP) does not express a preference for any type of vaccine. The Australian committee (ATAGI) preferably recommends adjuvanted influenza vaccine. The advisory committees of Canada and Germany (NACI, STIKO) and the European Center for Disease Control (Ecdc) recommend using any of the age-appropriate flu vaccines available, although they bet on the use of inactivated quadrivalent flu vaccine high dose at the individual level for those over 65 years. Conclusion. It is necessary further studies and improvement in their quality that analyze the different vaccines available and their comparability, although the use of reinforced immunity vaccines is generally recommended in the population over 65 years of age.

Download Full-text

Should safety of the flu vaccine for cancer patients be reexamined?

F1000Research ◽

10.12688/f1000research.13428.1 ◽

2018 ◽

Vol 7 ◽

pp. 1 ◽

Cited By ~ 4

Author(s):

Slobodan Paessler ◽

Veljko Veljkovic

Keyword(s):

Experimental Data ◽

Cell Proliferation ◽

Influenza Vaccine ◽

Cancer Patients ◽

Influenza Infection ◽

Cell Proliferation And Migration ◽

Seasonal Flu ◽

Flu Vaccine ◽

And Migration ◽

Proliferation And Migration

Seasonal flu vaccine is recommended as the best protection for cancer patients against influenza infection. Recent in silico and experimental data suggest that antibodies elicited with influenza vaccine could activate bradykinin receptor B2-associated signaling pathway, which is also involved in cell proliferation and migration of tumor cells. These results point to an urgent need for the reexamination of safety of influenza vaccine(s) in cancer patients.

Download Full-text